ACOR News and Press, Acorda Therapeutics Inc. From 07/03/19

Acorda Therapeutics ( ACOR ) has had a difficult year with the genericization of their AMPYRA asset coming from a court decision in September 2018. The company has lost over half of its equity value YTD and investors have been continually selling shares even amidst a strong bull market. Howe...

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...

Framing OFF Through Art℠ gallery illustrates individuals’ experience with OFF periods New research on OFF periods to be presented at conference plenary session Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that it will debut an art gallery inspired b...

I have been following Adamas Pharmaceuticals ( ADMS ) ever since they were able to receive FDA approval for their flagship product GOCOVRI for PD dyskinesia and OFF. Since then, I have started writing for Seeking Alpha and decided to write about my Adamas journey. Most of my writing has been f...

LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST. A live audio webcast of the presentation can be accessed under “...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q1 earnings Read more ...

Acorda Therapeutics ( ACOR ) Q1 results : Revenues: $44.1M (-58.5%); Ampyra sales: $41.3M (-59.9%); Royalty revenues: $2.8M (-12.5%); Inbrija sales: $1.3M. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Acorda Therapeutics (NASDAQ: ACOR ): Q1 Non-GAAP EPS of -$0.56 beats by $0.41 ; GAAP EPS of -$1.00. More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

INBRIJA™ (levodopa inhalation powder) commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximate...